Literature DB >> 21521163

Filariasis: Current status, treatment and recent advances in drug development.

D Katiyar1, L K Singh.   

Abstract

Lymphatic filariasis, onchocerciasis and loiasis caused by human filarial nematodes are diseases of tropical and subtropical countries causing considerable morbidity. The available control strategies have significant limitations such that current drugs are ineffective against macrofilariae (adult worms), require repeated and prolonged treatment over years and are threatened by emergence of drug resistance. Due to this concern, these diseases are the focus of renewed scientific interest and much has been done in filariasis research in the past decade. This review summarizes the current status of filariasis, different control strategies, recent advances in antifilarial chemotherapy including currently used drugs, their pros and cons, their mechanism of action, and recently discovered targets and prototypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521163     DOI: 10.2174/092986711795656234

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  9 in total

1.  In vitro evaluation of antifilarial effect of Azadirachta indica leaves extract in different solvents on the microfilariae of Setaria cervi.

Authors:  Sharba Kausar
Journal:  J Parasit Dis       Date:  2016-01-13

2.  Observations on in vitro and in vivo antimicrofilarial effects of Bishop's weed (Trachispermum ammi).

Authors:  Asim Rizvi; Rosina Khan; Asad Ullah Khan; Zeba Ghani; Saba Ghani; M Khalid Saifullah; M Saleemuddin; S M A Abidi
Journal:  J Parasit Dis       Date:  2011-10-13

3.  Virtual screening of traditional Chinese medicine (TCM) database: identification of fragment-like lead molecules for filariasis target asparaginyl-tRNA synthetase.

Authors:  Hemant Arya; Mohane Selvaraj Coumar
Journal:  J Mol Model       Date:  2014-05-20       Impact factor: 1.810

4.  The relevance of studying insect-nematode interactions for human disease.

Authors:  Zorada Swart; Tuan A Duong; Brenda D Wingfield; Alisa Postma; Bernard Slippers
Journal:  Pathog Glob Health       Date:  2021-11-02       Impact factor: 3.735

5.  Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis.

Authors:  Thanh Bach; Gregory A Deye; Ellen E Codd; John Horton; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.938

6.  Histamine 1 Receptor Blockade Enhances Eosinophil-Mediated Clearance of Adult Filarial Worms.

Authors:  Ellen Mueller Fox; Christopher P Morris; Marc P Hübner; Edward Mitre
Journal:  PLoS Negl Trop Dis       Date:  2015-07-23

Review 7.  Repurposing drugs for the treatment and control of helminth infections.

Authors:  Gordana Panic; Urs Duthaler; Benjamin Speich; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-07-30       Impact factor: 4.077

8.  Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.

Authors:  Robert T Jacobs; Christopher S Lunde; Yvonne R Freund; Vincent Hernandez; Xianfeng Li; Yi Xia; David S Carter; Pamela W Berry; Jason Halladay; Fernando Rock; Rianna Stefanakis; Eric Easom; Jacob J Plattner; Louise Ford; Kelly L Johnston; Darren A N Cook; Rachel Clare; Andrew Cassidy; Laura Myhill; Hayley Tyrer; Joanne Gamble; Ana F Guimaraes; Andrew Steven; Franziska Lenz; Alexandra Ehrens; Stefan J Frohberger; Marianne Koschel; Achim Hoerauf; Marc P Hübner; Case W McNamara; Malina A Bakowski; Joseph D Turner; Mark J Taylor; Stephen A Ward
Journal:  J Med Chem       Date:  2019-02-26       Impact factor: 7.446

9.  Transcriptomic analysis of insecticide resistance in the lymphatic filariasis vector Culex quinquefasciatus.

Authors:  Walter Fabricio Silva Martins; Craig Stephen Wilding; Alison Taylor Isaacs; Emily Joy Rippon; Karine Megy; Martin James Donnelly
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.